In a two phase trial of 69 children aged 4-17, with median disease duration of approx 6 years and active polyarticular juvenile idiopathic arthritis, treatment with etanercept at 400 mcg/kg was given for a maximum of 3 months.
74% of patients had a 30% improvement as measured in atleast 3 of 6 clinical parameters with no more than 1 measure worsening by more than 30%.
These "responders" were then entered into the second phase of the trial, and were randomised to continue etanercept or placebo for 4 months. Only 28% of those on etanercept experienced a flare in disease compared to 81% with placebo.
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.